Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd. is a pioneering Australian company specializing in the development of innovative treatments for UV and light-related skin disorders. Their flagship product, SCENESSE®, is the first systemic photoprotective drug approved for preventing phototoxicity in patients with erythropoietic protoporphyria. The company leverages its expertise in photomedicine and melanocortin peptides to address unmet medical needs globally.
Short position
Clinuvel Pharmaceuticals (ASX:CUV) has 9.07% of its shares on issue reported as short positions as of 5 Oct 2026, or about 4,572,694 shares. Over the past 30 days that figure has risen 0.96 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 10.04% in August 2020. CUV is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Clinuvel Pharmaceuticals (CUV) company profile
Profile, insiders and operations
Company
AI-generated research profile of Clinuvel Pharmaceuticals
CUV intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links